复杂PCI术后ACS患者普拉格雷降剂量治疗:HOST-REDUCE-POLYTECH-ACS试验事后分析
该研究为HOST-REDUCE-POLYTECH-ACS试验的事后分析,纳入2271例ACS行PCI患者,其中705例接受复杂PCI。结果显示,普拉格雷降剂量(5mg/日)较常规剂量(10mg/日)未增加MACE风险(复杂PCI HR 0.88, 95%CI 0.47-1.66),但降低BARC≥2级出血事件(复杂PCI HR 0.25, 95%CI 0.10-0.61),无论PCI复杂程度如何。
要点
- 复杂PCI患者中,普拉格雷降剂量未增加1年MACE风险。
- 复杂PCI患者中,降剂量显著降低BARC≥2级出血风险。
- 复杂PCI与更高的缺血事件率相关,但与出血事件无关。
核心结论
- 在ACS行PCI患者中,普拉格雷降剂量较常规剂量不增加缺血事件风险,可能减少1年轻微出血事件,且不受PCI复杂程度影响。
研究设计与样本
- HOST-REDUCE-POLYTECH-ACS试验的事后分析,随机、开放标签、盲法判定结局的多中心研究,在韩国35家医院进行。
- 纳入2271例ACS行PCI患者,其中705例接受复杂PCI,1566例接受非复杂PCI;平均年龄58.9岁(SD 9.0),男性2024例(89%)。
主要发现
- 复杂PCI与更高的缺血事件率相关,但与出血事件无关。
关键数值与推荐
- 复杂PCI定义:至少满足以下一项:植入≥3枚支架、处理≥3处病变、分叉PCI、总支架长度≥60 mm、左主干PCI或重度钙化。
- 主要分析终点:1年MACE(心血管死亡、非致命性心肌梗死、支架血栓和重复血运重建的复合终点)和1年BARC≥2级出血事件。
临床怎么用
- 对于ACS行PCI的患者,尤其是复杂PCI患者,普拉格雷降剂量(5mg/日)可在不增加缺血风险的情况下减少出血事件。
- 临床决策时应综合考虑患者的缺血和出血风险,个体化选择抗血小板治疗方案。
局限性
- 本研究为事后分析,结果需谨慎解读。
- 出血事件风险降低的95%CI较宽,尤其非复杂PCI组。
- 研究仅纳入韩国人群,可能限制普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: De-escalation of dual-antiplatelet therapy through dose reduction of prasugrel improved net adverse clinical events after acute coronary syndrome (ACS), mainly through the reduction of bleeding without an increase in ischemic outcomes. However, whether such benefits are similarly observed in those receiving complex procedures is unknown. OBJECTIVE: To investigate whether the benefits of prasugrel dose de-escalation therapy are maintained in the complex percutaneous coronary intervention (PCI) subgroup. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the HOST-REDUCE-POLYTECH-ACS trial, a randomized, open-label, adjudicator-blinded, multicenter trial performed at 35 hospitals in South Korea. Study participants included patients with ACS who were receiving PCI. Data were collected from September 30, 2014, to December 18, 2015, and analyzed from September 17, 2020, to June 15, 2021. INTERVENTIONS AND EXPOSURES: Patients were randomized to a prasugrel dose de-escalation (5 mg daily) at 1 month post-PCI group or a conventional (10 mg daily) group. Complex PCI was defined as having at least 1 of the following features: 3 or more stents implanted, 3 or more lesions treated, bifurcation PCI, total stent length 60 mm or larger, left main PCI, or heavy calcification. MAIN OUTCOMES AND MEASURES: The main analysis end points were MACE (major adverse cardiac event, a composite of cardiovascular death, nonfatal myocardial infarction, stent thrombosis, and repeat revascularization) at 1 year for ischemic outcomes, and BARC (Bleeding Academic Research Consortium) class 2 or higher bleeding events at 1 year for bleeding outcomes. RESULTS: Of 2271 patients (mean [SD] age, 58.9 [9.0] years; 2024 [89%] male patients) for whom full procedural data were available, 705 patients received complex PCI, and 1566 patients received noncomplex PCI. Complex PCI was associated with higher rates of ischemic outcomes but not with bleeding outcomes. Prasugrel dose de-escalation did not increase the risk of MACE (hazard ratio [HR], 0.88; 95% CI, 0.47-1.66; P = .70 in complex PCI; HR, 0.81; 95% CI, 0.45-1.46; P = .48 in noncomplex PCI; P for interaction = .84) but decreased BARC class 2 or higher bleeding events (HR, 0.25; 95% CI, 0.10-0.61; P = .002 in complex PCI; HR, 0.62; 95% CI, 0.38-1.00; P = .05 in noncomplex PCI; P for interaction = .08), albeit with wide 95% CIs. CONCLUSIONS AND RELEVANCE: In this post hoc analysis of patients with ACS, prasugrel dose de-escalation compared with conventional therapy was not associated with an increased risk of ischemic outcomes but may reduce the risk of minor bleeding events at 1 year, irrespective of PCI complexity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02193971.
引用
- Hwang, Lim, Park, et al. Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial. JAMA Cardiol. 2022. PMID: 35262625. doi:10.1001/jamacardio.2022.0052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。